U.S. markets closed
  • S&P Futures

    3,835.75
    +16.50 (+0.43%)
     
  • Dow Futures

    31,907.00
    +131.00 (+0.41%)
     
  • Nasdaq Futures

    12,365.75
    +68.50 (+0.56%)
     
  • Russell 2000 Futures

    2,211.00
    +10.20 (+0.46%)
     
  • Crude Oil

    65.19
    +0.14 (+0.22%)
     
  • Gold

    1,678.60
    +0.60 (+0.04%)
     
  • Silver

    25.20
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1841
    -0.0011 (-0.09%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3808
    -0.0014 (-0.10%)
     
  • USD/JPY

    109.1390
    +0.2380 (+0.22%)
     
  • BTC-USD

    53,373.95
    +1,916.02 (+3.72%)
     
  • CMC Crypto 200

    1,080.06
    +55.85 (+5.45%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,832.21
    +88.96 (+0.31%)
     

scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
scPharmaceuticals, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST.

A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.

About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.

Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
ktaudvin@scpharma.com

Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
hans@lifesciadvisors.com

Media:
Kate Coyle
ICR Inc., 203-682-8210
kate.coyle@icrinc.com